The recently launched BRCA Care program may increase test access in six countries, though it cannot ensure access to downstream interventions based on results.
Trial data, however, raised doubt about Lynparza's benefit in metastatic castration-resistant prostate cancer patients with non-BRCA1/2 HRR gene mutations.
After five years, nearly half the Lynparza-treated patients in the SOLO-1 trial remained disease-free, compared with one-fifth of those who received placebo.
Adult participants will have access to saliva-based testing from Invitae for the Screen Project, which aims to find clinically actionable BRCA1/2 mutations.
The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care.
